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Abstract: The cardiac effects of calcium channel blockers (CCBs)
related to cardiac remodeling are inconsistent. Matrix metalloprotein-
ases (MMPs) contribute to tissue remodeling. Cardiac fibroblasts
play an important role in the regulation of collagen degradation by
MMPs. Using gelatin zymography, Western blotting, Griess reagent,
and a calcium kit-fluo 3, we investigated the effects of nifedipine,
verapamil, diltiazem, and amlodipine on MMP-2 expression and fur-
ther elucidate the mechanisms in cultured rat cardiac fibroblasts. Ni-
fedipine increased and amlodipine decreased the expression of
MMP-2; however, neither verapamil nor diltiazem altered MMP-2
expression. Nifedipine also increased nitrite production, and this in-
crease was blunted by a nitric oxide (NO) synthases inhibitor (L-
NAME). Nifedipine-induced MMP-2 expression was also blunted by
L-NAME. An NO donor (sodium nitroprusside) induced MMP-2 ex-
pression. Data indicated that nifedipine might increase MMP-2 ex-
pression through a possible NO-dependent pathway. Amlodipine had
no influence on nitrite production. The amlodipine-induced decrease
of MMP-2 expression was abolished by two protein tyrosine kinase
inhibitors, genistein and herbimycin A, indicating that amlodipine
might decrease MMP-2 expression through a possible protein tyro-
sine kinase pathway. None of the four CCBs could alter the fluosce-
nce intensity of fluo 3, indicating that the effects of CCBs on MMP-2
expression were independent of the variation in intracellular Ca2+
concentration. Our findings revealed that different CCBs exerted dif-
ferent effects on MMP-2 expression in cardiac fibroblasts.
Key Words: calcium channel blocker, matrix metalloproteinase,
fibroblasts, nitric oxide, protein tyrosine kinase
(J Cardiovasc Pharmacol™ 2004;44:223–230)
Myocardial extracellular matrix remodeling has been pro-posed to participate in the development of ventricular
dilatation and heart failure. The extracellular matrix of the
heart includes a fibrillar collagen network, a basement mem-
brane, and proteoglycans.1 The matrix metalloproteinases
(MMPs) are a family of zinc-dependent enzymes demon-
strated to contribute to tissue remodeling in a number of dis-
ease states.2 MMP-2 is one of the MMPs that may have par-
ticular relevance to myocardial remodeling.1 The potent
gelatinase, MMP-2, can also cleave fibrillar collagen3 in addi-
tion to the basement membrane.4 Increased MMP-2 activity in
heart failure has been identified in humans.5 MMP activity
contributed to left ventricular dilation and progression to left
ventricular dysfunction in a rodent heart failure model, and
direct MMP inhibition can attenuate this process.6
Calcium channel blockers (CCBs) are potent vasodila-
tors widely used in the treatment of hypertension and angina
pectoris. However, unwanted cardiac performance of CCBs
has been reported and is thought to act via negative inotropic
effects and neurohormonal activation.7 The adverse effects of
CCBs may be attributable to direct cardiodepressant action of
these drugs on an already dysfunctioning myocardium.7 Re-
cently, CCBs have been shown to limit cardiac remodeling and
improve cardiac function in myocardial infarction-induced
heart failure in rats.8 On the other hand, biphasic survival re-
sponse to amlodipine after myocardial infarction in rats has
been recently reported to be associated with cardiac vascular
remodeling.9 These results prompted us to examine the effects
of the CCBs on processes related to cardiac remodeling.
Nearly all CCBs used clinically act on the L-type calcium chan-
nels and belong to 3 distinct classes of compounds, including
dihydropyridines (eg, nifedipine, amlodipine), benzothiaz-
epines (eg, diltiazem), and phenylalkylamines (eg, verapam-
il).10 Therefore, we selected nifedipine, diltiazem, verapamil,
and amlodipine as CCB representatives.
Fibroblasts are the most abundant cell type in the heart
and play a major role in synthesizing components of the car-
diac extracellular matrix.11 Cardiac fibroblasts have also been
shown to play an important role in the regulation of collagen
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degradation by MMPs.12 Therefore, the present study was de-




The chemicals used in this study were obtained from
the following sources: Dulbecco modified Eagle medium
(DMEM) was obtained from GIBCO (Grand Island, NY); ni-
fedipine was kindly supplied by Bayer Japan (Osaka, Japan).
Amlodipine was obtained from Sumitomo Pharmaceuticals
(Osaka, Japan). NG-nitro-L-arginine methyl ester (L-NAME)
was purchased from Sigma Chemical Co. (St. Louis, MO).
Sodium nitroprusside (SNP) was obtained from ICN Biomedi-
cal Inc. (Aurora, OH). Mouse monoclonal Anti-MMP-2 anti-
body was obtained from Fuji Chemical Industries (Toyama,
Japan). Genistein and herbimycin A were purchased from
Wako (Osaka, Japan). Calcium Kit–Fluo 3 was obtained from
Dojindo Laboratories (Tokyo, Japan). All other chemicals
were of reagent grade or were the highest grade commercially
available.
Cell Culture
The animal protocols used in this experiment were re-
viewed by the Institutional Animal Care and Use Committee at
Fukui University. Primary cultures of neonatal rat cardiac fi-
broblasts were prepared as previously described with some
modifications.13 Briefly, hearts were removed from 1- to
2-day-old Wistar rats anesthetized by ether under aseptic con-
ditions and placed in Ca2+ and Mg2+ free phosphate-buffered
saline (PBS). The hearts were washed with PBS, and the atria
and aorta were discarded. The ventricles were minced with
scissors into 1- to 3-mm3 fragments, and they were then enzy-
matically digested 4 times for 10 to 15 minutes each with 10
mL of PBS containing 0.07% trypsin. The liberated cells were
collected by centrifugation at 1000 × g for 5 minutes and in-
cubated in 100-mm glass culture dishes for 60 minutes at 37°C
in a humidified incubator with 5% CO2–95% air. During this
time, the majority of myocardiocytes remained in suspension,
whereas the nonmyocardiocytes attached more readily to the
dish. Subsequently, the medium containing the myocardio-
cytes was aspirated and discarded. Highly enriched cultures of
cardiac nonmyocytes were prepared by 2 passages of the cells
adherent to the culture dish during the replating procedure.14
Until the second passage, cells were maintained in DMEM
supplemented with 10% fetal calf serum. The nature of cells
was determined by immunofluorescence staining with anti-
vimentin for identification of fibroblasts, and more than 95%
of the cells were stained positively. Cardiac fibroblast cultures
between passages 3 and 4 were used in this study. To deter-
mine whether signal transduction pathways were modified
during cell culture, acute isolate fibroblasts were also used.
Gelatin Zymography
Cardiac fibroblasts were plated in 6-well plates (5 × 104
cells/well), incubated at 37°C in a humidified atmosphere of
95% air–5% CO2, and maintained in DMEM with 10% fetal
calf serum until subconfluent. The subconfluent cells were se-
rum deprived and treated with CCBs (nifedipine, verapamil,
diltiazem, and amlodipine between concentrations of 10−9 M
to 10−6 M), SNP, or in combination with L-NAME for 24
hours. After treatment, media were harvested, centrifuged at
2000 × g for 10 minutes and normalized for cell protein content
using a Bio-Rad assay. Samples of 20 µg protein were applied
without reduction to a 7.5% polyacrylamide slab gel impreg-
nated with 1 mg/ml gelatin.15 After electrophoresis, the gel
was washed at room temperature for 30 minutes in washing
buffer (50 mM Tris-Cl, pH 7.5, 15 mM CaCl2, 1 µM ZnCl2,
and 2.5% Triton X-100), then incubated overnight at 37°C
with shaking in the same buffer but containing 1% rather than
2.5% Triton X-100. The gel was stained with a solution of
0.1% Coomassie brilliant blue R-250. Clear zones against the
blue background indicated the presence of gelatinase. To
quantify the amount of gelatinase production, the stained zy-
mograms were scanned on a densitograph (ATTO, Tokyo, Ja-
pan) as described previously.16 A protein marker and control
MMPs (Sigma-Aldrich, St. Louis, MO) were electrophoresed
in parallel for molecular weight identification.
Western Blotting
After various treatments for 24 hours, medium samples
were harvested with the protease inhibitors phenylmethane
sulfonyl fluoride (0.1 mM) and leupeptin (10 µg/ml), centri-
fuged at 2000 × g for 10 minutes, protein concentration was
measured and separated by electrophoresis on 7.5% sodium
dodecyl sulfate (SDS) polyacrylamide gels followed by trans-
fer onto polyvinylidene diflouride membranes (Immobilon P,
Millipore, 0.22 µm pore size). The membranes were blocked in
5% skim milk in phosphate buffered saline containing 0.1%
Tween 20 at room temperature for 1 hour, and probed with
anti-human MMP-2 monoclonal antibody overnight. After
washing 3 times with PBS containing 0.1% Tween 20, the
membranes were incubated with secondary antibody conju-
gated with horseradish peroxidase for 1 hour as described pre-
viously,17 and finally developed by ECL detection system
(Amersham Pharmacia Biotech, Buckinghamshire, England).
Intracellular Calcium Variation
Intracellular calcium variations were evaluated with a
Calcium Kit–Fluo 3, as previously described18 and the proce-
dure provided by Dojindo Laboratories (Tokyo, Japan).
Briefly, cardiac fibroblasts were seeded in 96-well microplates
at 1.5 × 104 cells/well and cultured overnight. After treatments
with various CCBs of different concentrations in extracellular
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calcium concentrations of 1.8 mM and 0 mM, the cells were
loaded with loading buffer containing 6 µM fluo 3, 1.25 mM
probenecid, and 0.04% pluronic F-127, incubated at 37°C for
1 hour. The cells were then continuously bathed in recording
buffer containing no indicator. The wavelength of emission for
analysis was 538 nm and of excitation was 485 nm. Changes in
the fluoscence intensity of fluo 3 in the cells that indicated the
variation of intracellular calcium were recorded with a Fluo-
roskan Ascent (Labsystems, Helsinki, Finland).
Nitrite Production
Nitrite production, an indicator of nitric oxide (NO) syn-
thesis, was measured by adding of 100 µL of Griess reagent
(1% sulfanilamide and 0.1% naphthylethylenediamide in 5%
phosphoric acid) to 100 µL samples of cell culture medium.19
The optical density at 540 nm (OD540) was measured using a
Maxline Microplate Reader (Molecular Devices Corporation,
Sunnyvale, CA). Nitrite concentrations were calculated by
comparison with OD540 of a standard solution of sodium nitrite
prepared in culture medium. The amount of nitrite production
was normalized for cell protein content using a Bio-Rad assay.
Statistical Analysis
Results were presented as percentages of the control and
represent the means ± standard errors (SE) for 4 separate ex-
periments performed in duplicate. Differences among all data
were analyzed for significance by one-way analysis of vari-
ance (ANOVA) followed by unpaired Student t test. Differ-
ences of P < 0.05 were considered significant.
RESULTS
Effects of Calcium Channel Blockers on the
Expression of MMP-2 in Cardiac Fibroblasts
Gelatin zymograms of cardiac fibroblasts-conditioned
media showed that the major MMP expressed was MMP-2.
Nifedipine increased and amlodipine decreased the gelatino-
lytic activity of MMP-2 significantly in a dose-dependent
manner. However, neither verapamil nor diltiazem influenced
the MMP-2 activity (Fig. 1A). These effects were not toxic as
determined by trypan blue exclusion.
Corresponding with the data of gelatin zymography,
Western-blotting analysis demonstrated that nifedipine in-
duced an increase, and amlodipine induced a decrease in
MMP-2 expression dose dependently (Fig. 1B).
Enzymatic activity of MMP-2 was inhibited after the ad-
dition of 10 mM EDTA, an inhibitor of MMPs, into the incu-
bating buffer. In contrast, gelatinolytic bands displayed after
zymography were unaffected by incubation in phenylmethyl-
sulfonyl fluoride, an inhibitor of serine proteases (data not
shown).
Effects of Calcium Channel Blockers on the
Variation of Intracellular Calcium in
Cardiac Fibroblasts
To ascertain how CCBs could interfere with intracellular
calcium, changes in the fluoscence intensity of fluo 3 in the
cardiac fibroblasts were recorded. None of the CCBs, nifed-
ipine, verapamil, diltiazem, and amlodipine could signifi-
cantly alter the fluoscence intensity of fluo 3 (Fig. 2). When
extracellular calcium was removed, there was approximately
43% less fluo 3 fluoscence intensity; however, none of the
CCBs could alter the fluoscence intensity (Fig. 2). Calcium
FIGURE 1. Effects of calcium channel blockers on MMP-2 ex-
pression in cardiac fibroblasts. Nifedipine (a) induced a signifi-
cant increase, and amlodipine (d) induced a significant de-
crease in MMP-2 expression in a dose-dependent manner, but
verapamil (b) and diltiazem (c) did not alter MMP-2 expres-
sion, as determined by zymography (A) and Western blotting
(B). Clear zones against the blue background indicate the pres-
ence of MMP-2. Data of gelatinolytic activity are presented as
percentages of the amount of control and represent the mean
 standard error (SE) for 4 separate experiments performed in
duplicate. *P < 0.05 versus control, **P < 0.01 versus control,
***P < 0.001 versus control.
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signal characteristics were not correlated with the number of
passages in cell culture as confirmed by a study performed in
acutely isolated fibroblasts (data not shown).
Effects of Calcium Channel Blockers on the
Production of Nitrite in Cardiac Fibroblasts
To determine whether CCBs could alter NO synthesis,
nitrite production of cardiac fibroblast-conditioned media
were studied. The addition of nifedipine to cardiac fibroblasts
in serum-free medium caused a significant increase in nitrite
production in a dose-dependent manner, indicating that nifed-
ipine increased NO synthesis. However, the other 3 CCBs
studied (verapamil, diltiazem, and amlodipine) had no influ-
ence on nitrite production at any concentration (Fig. 3).
To exclude the possibility that the nifedipine preparation
contained lipopolysaccharide, several different preparations of
nifedipine—with dimethyl sulfoxide, ethanol, and polyethyl-
ene glycol 400 (at 60°C) in the possible lowest concentration
were compared. No differences were found in nitrite produc-
tion of nifedipine prepared by any method (data not shown),
indicating that the effect of nifedipine on nitrite production
was inherent rather than from lipopolysaccharide contained in
the preparation.
Effects of Sodium Nitroprusside on MMP-2
Expression in Cardiac Fibroblasts
To determine the effects of NO on gelatinase expression
in cardiac fibroblast-conditioned media, we added an exog-
enous NO donor, SNP (ranging from 10−7 M to 10−3 M), to
cardiac fibroblast cultures for 24 hours. SNP induced an in-
crease on MMP-2 expression markedly and dose dependently
(Fig. 4).
Effects of L-NAME on Nitrite and MMP-2
Expression Induced by Nifedipine
To evaluate whether the effects of nifedipine on expres-
sion of MMP-2 were related to NO, subconfluent cardiac fi-
broblasts were treated with an NO synthase inhibitor-L-
NAME for 30 minutes before treatment with nifedipine in
culture media from concentrations of 10−9 M to 10−6 M for 24
hours. The pretreatment of L-NAME blunted both the in-
creased nitrite and MMP-2 expression induced by nifedipine
(Fig. 5A, B), indicating a possibility that nifedipine affected
MMP-2 expression via a pathway related to NO, at least in
part.
Effects of Protein Tyrosine Kinase Inhibitors on
Calcium Channel Blocker-Induced Alteration
on MMP-2 Expression in Cardiac Fibroblasts
To evaluate whether the effects of amlodipine and nifed-
ipine on expression of MMP-2 were related to protein tyrosine
kinase, subconfluent cardiac fibroblasts were separately
FIGURE 3. Effects of calcium channel blockers on nitrite pro-
duction in cardiac fibroblasts. Nifedipine caused a significant
increase in nitrite production in a dose-dependent manner as
determined by Griess reagent. However, verapamil, diltiazem,
and amlodipine did not influence nitrite production at any
concentration. Data represent the mean standard error (SE)
for 4 separate experiments performed in duplicate. *P < 0.05
versus control, ***P < 0.001 versus control.
FIGURE 2. Effects of CCBs on the variation of intracellular cal-
cium in cardiac fibroblasts. The variation of intracellular cal-
cium in cardiac fibroblasts was determined by the change of
the fluoscence intensity of fluo 3. None of the CCBs, nifed-
ipine, verapamil, diltiazem, or amlodipine, could significantly
alter the fluoscence intensity of fluo 3 in the presence or ab-
sence of extracellular calcium. Columns indicate data of fluos-
cence intensity as percentages of the amount of basal condi-
tion in the presence of extracellular calcium, and represent the
means  standard error (SE) for 4 separate experiments per-
formed in duplicate.
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treated with 2 protein tyrosine kinase inhibitors, genistein and
herbimycin A, for 10 minutes before treatment with amlo-
dipine or nifedipine in culture media from concentrations of
10−9 M to 10−6 M for 24 hours. Both genistein (10 µM) and
herbimycin A (0.5 µg/ml) abolished the decrease in MMP-2
expression induced by amlodipine (Fig. 6); however, neither
genistein nor herbimycin A influenced the increase in MMP-2
expression induced by nifedipine (data not shown), indicating
that amlodipine, but not nifedipine, might affect MMP-2 ex-
pression through a possible pathway related with a protein ty-
rosine kinase.
DISCUSSION
The present findings demonstrate for the first time that 2
CCBs, nifedipine and amlodipine, increase and decrease re-
spectively the expression of MMP-2 through different possible
related pathways, while neither verapamil nor diltiazem influ-
enced MMP-2 expression in cardiac fibroblasts. Previous find-
ings demonstrated that nifedipine and amlodipine had opposite
effects on nitrite production in isolated hearts,20 and may pro-
vide support to our investigation.
Although increased MMP-2 activity in heart failure has
been identified in humans,5 the dynamic process of ventricular
remodeling with both above and below normal MMP activity
and collagen concentration had been pointed out21 and shown
in transgenic mice with cardiac restricted overexpression of
tumor necrosis factor that developed into progressive left ven-
tricular remodeling.22 Both potentially beneficial and poten-
tially detrimental aspects of MMPs on myocardial injury and
repair have been pointed out.23 Furthermore, MMP-2 had been
shown to degrade interleukin-1,24 while inflammatory cyto-
kines such as interleukin-1 exert a number of actions that may
be important in myocardial remodeling and failure.25 There-
fore, although nifedipine increased MMP-2 expression differ-
ently than amlodipine, we cannot conclude whether or not the
effects of nifedipine or amlodipine are beneficial. However,
our data indicated that the various effects of CCBs on ventricu-
lar remodeling or heart failure might be related to the different
effects of CCBs on MMP-2 expression in cardiac fibroblasts,
at least in part. How and when to use the different CCBs ben-
eficially according to their different characters on MMP-2 is
important and needs to be examined in future studies.
The maximum concentration of nifedipine (10−6 M)
used in our study was higher than clinical plasma concentra-
tions reported (about 0.2 µM).26 It had been shown that nifed-
ipine may accumulate in membranous structures, resulting in
higher localized concentrations of the compound.27 Further-
more, it has been accepted that high in vitro concentrations of
CCBs are required to achieve pharmacological effects, and
such concentrations have been used by others.28 Therefore, all
maximum CCB concentrations used in the present study were
selected as 10−6 M, and no cytotoxic effects were found as
detected by trypan blue.
FIGURE 4. Effects of SNP on MMP-2 expres-
sion in cardiac fibroblasts. SNP, an exogenous
NO donor, induced an increase in MMP-2 ex-
pression significantly and dose dependently
as detected by gelatin zymography. Clear
zones against the blue background indicate
the presence of MMP-2. Columns indicate
data of gelatinolytic activity as percentages of
the amount of control, and represent the
means  standard error (SE) for 4 separate
experiments performed in duplicate. **P <
0.01 versus control, ***P < 0.001 versus con-
trol.
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Pathways to oscillate intracellular calcium are com-
prised mainly of: (1) various calcium channels in cell mem-
brane (receptor-mediated calcium channels, voltage-depen-
dent calcium channels, non-specific cation channels); (2) Na+-
Ca2+ exchange; (3) release of intracellular calcium store.29
Cardiac fibroblasts have been shown to release calcium from
intracellular stores30,31 and from extracellular calcium in-
flux.31,32 In the present study, none of the CCBs, nifedipine,
verapamil, diltiazem, or amlodipine, could significantly alter
the fluoscence intensity of fluo 3 in the presence or absence
of extracellular calcium, indicating that the effects of CCBs
on MMP-2 expression were independent of the variation in
intracellular Ca2+ concentration. A recent report that lacid-
ipine, a third-generation dihydropyridine calcium antagonist,
inhibited MMP-9 secretion in human macrophages, indepen-
dent of the variation in intracellular Ca2+ concentration,33 sup-
ports our present study. Therefore, there may be some other
mechanisms for nifedipine and amlodipine to exert their ef-
fects on MMP-2 expression in cardiac fibroblasts independent
of intracellular calcium variation.
NO is a free radical with an unpaired electron and is
an important physiological messenger, produced by nitric
oxide synthases that catalyze the reaction L-arginine to
citrulline and NO. Evidence has accumulated that NO may me-
diate or contribute to the calcium channel-independent effects
of CCBs. Ding and Vaziri10 showed recently that nifedipine
and diltiazem enhanced NO generation in cultured human
coronary artery endothelial cells while no such effect was ob-
served with verapamil. Because no L-type calcium channel has
FIGURE 6. Effects of protein tyrosine kinase inhibitors on am-
lodipine-induced MMP-2 expression in cardiac fibroblasts.
Amlodipine-induced decrease in MMP-2 expression was abol-
ished by the 2 protein tyrosine kinase inhibitors, genistein and
herbimycin A. Clear zones against the blue background indi-
cate the presence of MMP-2. Lanes 1 to 5 represent amlo-
dipine groups with concentrations of 109 M to 106 M, and
lanes 6 to 10 represent combined treatment groups of herbi-
mycin A (a) and genistein (b) with amlodipine of 109 M to
106 M, separately shown by zymography (A). The statistical
data are shown in B. Columns indicate data of gelatinolytic
activity as percentages of the amount of control, and represent
the means  standard error (SE) for 4 separate experiments
performed in duplicate. *P < 0.05 versus amlodipine 107 M,
**P < 0.01 versus amlodipine 106 M.
FIGURE 5. Effects of L-NAME on nitrite and MMP-2 expres-
sion induced by nifedipine. The nifedipine-induced nitrite (A)
and MMP-2 (B) expression were significantly suppressed by
L-NAME. Data represent the mean standard error (SE) for 4
separate experiments performed in duplicate.
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been observed in endothelial cells,34 the CCBs must exert
these effects via other mechanisms. Berkels et al28 showed that
the treatment of endothelial cells with nifedipine increased NO
release due to an enhanced availability of NO by antioxidative
protection. In the present study, nifedipine increased NO pro-
duction in a dose-dependent manner, in the same degree with
the studies mentioned above.10,28 There is much controversy
as to the biologic activity of NO, whether it increases or de-
creases in left ventricular hypertrophy.35 The diverse biologic
actions of coronary endothelial NO during the progression of
cardiac hypertrophy indicate that there is an increase in the
basal activity of NO in early compensated left ventricular hy-
pertrophy, followed by a decrease in both endothelial NO syn-
thase expression and NO bioactivity during the transition to
myocardial failure.35 Whether and when the increase or de-
crease of NO is beneficial is a subject beyond the present
study, but the present study emphasizes that, at least in cardiac
fibroblasts, CCBs might affect NO production differently to
mediate their intracellular calcium-independent effects, at
least in part.
Nitric oxide is recognized as an important signal mol-
ecule between and within cells.36 Recent studies suggest that a
complex relationship exists between NO and MMPs in cul-
tured fibroblasts. Findings that increased NO generation by an
NO donor, SNAP, stimulated the production of 72 kDa
MMP-2 in rheumatoid synovial fibroblasts suggest that NO
may play a critical role in regulating articular extracellular ma-
trix remodeling in rheumatoid arthritis through the production
of MMP-2.37 Others investigated the presence of NO-
mediated augmented regulation of MMP-1 production in cul-
tured human uterine cervical fibroblasts.38 In the present
study, L-NAME, an NO synthase inhibitor, significantly
blocked the inducing effect of nifedipine on MMP-2 in rat car-
diac fibroblasts, and SNP increased MMP-2 expression. These
results suggest that the alteration in expression of MMP-2 in-
duced by nifedipine might be related, at least in part, to NO.
As opposed to nifedipine, which increased both MMP-2
and nitrite expression, amlodipine decreased MMP-2 expres-
sion but had no influence on nitrite production; therefore, there
must be another signal pathway mediating the decreasing ef-
fect of amlodipine on MMP-2 expression in rat cardiac fibro-
blasts. Protein phosphorylation on tyrosine residues by protein
tyrosine kinases is an important regulator of cell function.39 Li
et al40 and our laboratory41 have demonstrated that MMP-2
production or activation was induced through protein tyrosine
phosphorylation. Therefore, it is plausible to assume that a pro-
tein tyrosine kinase pathway may play a role in the decreasing
effect of amlodipine on production of MMP-2 in cardiac fibro-
blasts. In the present study, we observed that the amlodipine-
induced decrease in MMP-2 expression was abolished by ei-
ther genistein or herbimycin A, both protein tyrosine kinase
inhibitors. Therefore, our data indicated that the effects of am-
lodipine on expression of MMP-2 in rat cardiac fibroblasts
might be mediated via a protein tyrosine kinase related path-
way. The different roles of tyrosine kinases in the present study
and our previous study41 might be attributable to the different
cell types used—cardiac fibroblasts and vascular smooth
muscle cells.
CONCLUSION
It is of interest to note that we found, at least for cardiac
fibroblasts, that the same dihydropyridine group L-type CCBs,
nifedipine and amlodipine, act differently on MMP-2 expres-
sion (increase and decrease, respectively), and may be medi-
ated independently via different pathways—NO and protein
tyrosine kinase related pathways, but not the variations of in-
tracellular calcium concentration. Verapamil and diltiazem,
however, did not influence MMP-2 expression. Our findings
revealed that different CCBs exerted different effects on
MMP-2 expression in cardiac fibroblasts.
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